Background {#S0001}
==========

Cortical subarachnoid hemorrhage (cSAH) is a rare form of subarachnoid hemorrhage characterized by unique imaging findings. Diagnosis is challenging given its subtle findings, and management is empiric as there are only a few case series in literature \[[@B1]\]. Incidence of this disease is not known, but case series estimate that cSAH represent 7.5--19% of all subarachnoid hemorrhage. Given that incidence of subarachnoid hemorrhage is 10--15 per 100,000 person years, a rough estimate places incident of cSAH on order of 0.7--2.8 per 100,000 person years \[[@B7]\].

Initially, cSAH can present as a small, cortical hyperdensities found on CT head. Due to its size, it can be difficult to be seen and often requires MRI to further characterize the finding. Fluid-attenuated inversion recovery and diffusion-weighted imaging sequences are more sensitive, and can show increased signal along one to a few sulci without spread to fissures, cisterns or ventricles \[[@B4]\]. Gradient echo (GRE) T2-weighted imaging can show hemoglobin degradation products, which are supportive of the presence of surface microbleeds \[[@B1]\]. GRE can also show hemosiderosis which occur outside time frame of acute bleed \[[@B2]\].

These imaging findings can be difficult to distinguish between other etiologies such as metastasis, cerebral venous thrombosis and vascular malformations. Additional testing is required to evaluate for alternative diagnoses \[[@B4]\]. In this case report, we discuss initial testing and long-term management.

Case discussion {#S0002}
===============

Our patient was a 66-year-old right-handed woman with a history of hypertension, hyperlipidemia and breast cancer (currently in remission after left mastectomy years ago). The patient stated she woke up by a phone call at 06:30, and was at baseline. During the phone conversation, she developed left arm numbness and weakness while holding her phone. Her symptoms were sudden onset and lasted approximately 10 min with spontaneous resolution. She did not have similar episodes in the past. Then, she had a second episode at 08:10, this time lasting approximately 40 min. She delayed presenting to ED until later afternoon, 9 h after symptom onset. On review of systems, she also complained of a gradual onset, vertex headache that started after she noticed her numbness.

On neurologic examination, she was alert and oriented to person, place and time. Her speech was fluent, comprehension was intact and fund of knowledge was good. She had mild left facial asymmetry and left pronator drift that later resolved. She had no other cranial nerve or motor findings. Numbness resolved at time of initial evaluation, and there were no further sensory changes. The remainder of her examination was unremarkable. No early signs of acute stroke was found on head CT, but there was small hyperdensity in right parietal sulci. Tissue plasminogen activator (TPA) alteplase was not given.

The patient was admitted for further workup. MRI was negative for areas of restricted diffusion, but there was abnormal signal within the sulci of right parietal postcentral sulcus. This lesion was hyperintense on fluid-attenuated inversion recovery ([Figure 1](#F0001){ref-type="fig"}) and isointense on T1 ([Figure 2](#F0002){ref-type="fig"}). GRE shows positive signal in area of the lesion, but otherwise no additional microbleeds were found ([Figure 3](#F0003){ref-type="fig"}). Magnetic resonance angiogram of head and neck showed mild narrowing of the posterior circulation vessels, but otherwise there was no significant stenosis or aneurysm.

![**Fluid-attenuated inversion recovery imaging findings.**\
**(A)** Axial FLAIR recovery shows linear hyperintensity in right parietal sulcus. **(B)** Arrow demonstrates finding on coronal FLAIR.\
FLAIR: Fluid-attenuated inversion recovery.](fnl-11-231-g1){#F0001}

![**Finding is isointense on T1.**](fnl-11-231-g2){#F0002}

![**Gradient-recalled echo MRI demonstrates linear susceptibility in right parietal sulcus consistent with subarachnoid blood.**](fnl-11-231-g3){#F0003}

The differential diagnosis for this finding included subarachnoid hemorrhage, venous thrombosis, meningitis and carcinomatosis. Appropriate workup for these etiologies was pursued. MRI with contrast showed the lesion was enhancing, but no other enhancing lesions were found. Magnetic resonance venography was also performed, and was negative for venous thrombosis. She was further evaluated with cerebrospinal fluid study, which demonstrated: RBC 1, WBC 1, glucose 90 and protein 22. Cytology was negative for atypical cells. Infectious workup included testing for herpes simplex virus, West Nile, cytomegalovirus and varicella zoster virus, which were negative. Bacterial and fungal cultures were negative. After 1 week hospital stay, there were no further episodes of numbness or weakness, and the patient was discharged.

Patient was seen 2 weeks later at outpatient follow-up. Given her age, clinical picture and imaging finding or cortical sulci hemorrhage, she fulfilled Boston criteria for possible cerebral amyloid angiopathy (CAA) \[[@B8]\]. She was advised that she may need long-term follow-up for her increased risk of vascular complications and intracranial hemorrhage. In addition, she was started on oxcarbazepine for possible seizures as cause of her symptoms. It was later discontinued due to poor compliance. Subsequently, she was started on gabapentin, and had no further headache or focal neurologic deficits. At 6 months follow-up, she continued to report resolution of symptoms.

Discussion {#S0003}
==========

A wide range of pathologies can cause cSAH, and the common ones found in case series include posterior reversible encephalopathy syndrome, vasospasm and CAA. Etiology may also be different with age. Kumar *et al*. found that in patients younger 60, the most common cause of cSAH was reversible cerebral vasoconstriction syndrome, while CAA was the most common etiology observed in patients older than 60. One study used Boston criteria for diagnosis of possible CAA \[[@B2]\]. To fulfill this criteria, the patient must be older than 55 years of age, and clinical picture and imaging must fit the diagnosis. Other etiologies may present with similar imaging findings, and they need to be ruled out. These include cerebral venous thrombosis, coagulopathies, leptomeningeal metastasis and vascular malformations \[[@B8]\].

Given that cSAH can be secondary to any of a variety of causes, its prognosis and management rests on treating the primary disease whenever possible \[[@B9]\]. Its initial workup should screen for potential life-threatening conditions. Unlike conventional subarachnoid hemorrhage, cSAH is not associated with saccular aneurysm. However, vessel imaging with magnetic resonance angiogram, magnetic resonance venography and CT angiogram is critical in screening for other vascular abnormalities \[[@B6]\]. Conventional angiogram should be prioritized in younger patients as they have higher risk of reversible cerebral vasoconstriction syndrome \[[@B3]\].

MRI of brain can further characterize the lesion, and identify characteristic signs of associated conditions such as CAA. Next, consider lumbar puncture, echocardiogram and appropriate cancer screening to rule out infectious and neoplastic causes. If workup is negative, then long-term follow-up is needed as these patients have higher risk of stroke and intracerebral hemorrhage \[[@B6]\]. Last, this case report and others have shown that antiepileptic medications can treat recurrent focal neurologic symptoms associated with this disease.

Conclusion {#S0004}
==========

The imaging findings in this case were typical for cSAH. The lesion was found within one cortical sulcus and was small in size. Two common symptoms seen in the literature are severe headache and/or recurring transient focal neurologic symptoms (such as sensory/motor deficits and aphasia) \[[@B10]\]. The exact mechanism is unknown. Current hypotheses include spreading cortical depression, focal seizures or vasospasm-induced transient ischemic attack \[[@B3]\]. In one case series, starting an antiepileptic drug was effective in preventing recurrent neurologic symptoms in four out of five patients \[[@B2]\]. This is only case report, that we know of, that shows gabapentin is an effective treatment after long-term follow-up.

Future Perspective {#S0005}
==================

Current understanding of this condition are mainly derived from single-center restrospective reviews. These studies are limited by lack of standardized diagnostic testing and treatment regimen. In future, multi-center studies are needed to confirm single center observations on longer term prognosis, associated conditions, and optimal treatment. For patients with recurrent focal neurologic symptoms, anti-epileptic drug treatment will become more prevalent. As more patients are treated, information will become available regarding effectiveness of anti-epileptic drugs. Additional studies are needed regarding whether prophylactic treatment is beneficial and whether certain medication regimens are more effective than others.

###### EXECUTIVE SUMMARY

1.  Cortical subarachnoid hemorrhage (cSAH) can present with headache and recurrent focal neurologic symptoms.

2.  Key feature of cSAH is hemorrhage in one or a few sulci without extension into parenchyma or ventricles.

3.  cSAH is rare disease and management is tailored to the patient.

4.  Differential for imaging of cSAH includes infection, neoplasm and vascular disease.

5.  All patients with cSAH need MRI, vessel imaging and cerebrospinal fluid studies to rule out alternative disease processes.

6.  Older patients are more likely to have cSAH due to cerebral amyloid angiopathy. Younger patients are more likely to have cSAH due to vasospasm.

7.  Focal neurologic symptoms may be due to transient ischemic attack, seizure or spreading cortical depression.

8.  Case reports show antiepileptic drugs may be effective for preventing recurrent symptoms.
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